Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T11:16:13.777Z.
Consensus retrieved: 2026-10-06T10:26:58.933Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T11:16:13.777Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4d2318746ff6c9807638b14c6da6d4403aeb01b385a412a6fbcdb911b1dd0b82
Forward PE Ratio (N/A) = Dated Quote Price ($122.03) / Consensus Forward EPS ($2.06)
FORWARD PE RATIO
N/A
Corcept Therapeutics Incorporated
Market Cap
$13.19B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Corcept Therapeutics Incorporated (CORT) | $13.19B | N/A |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 15.90 |
| Baxter International Inc. (BAX)vs › | $12.52B | 11.79 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 67.36 |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | N/A |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 34.10 |
| Encompass Health Corporation (EHC)vs › | $12.00B | 19.79 |
| Tempus AI, Inc. (TEM)vs › | $14.64B | N/A |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 16.75 |
Trailing P/E
290.6
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.06 implies +390.5% EPS growth vs the reported trailing $0.42.
At the dated quote price of $122.03, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.06 | $1.54 – $2.44 | 4 | 59.2x |
| 2027-12-31 | $4.29 | $2.53 – $5.01 | 4 | 28.4x |
| 2028-12-31 | $7.12 | $3.72 – $11.63 | 4 | 17.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
